Treatment Details
Molnupiravir
Overview
MOLNUPIRAVIR What is molnupiravir (Lagevrio). Molnupiravir, a medication authorized by the FDA in 2021 for Emergency Use, is used to treat COVID-19 infections [1]. It is an antiviral that changes the genetic makeup of COVID-19, so it cannot replicate. For the best outcome, molnupiravir should be used within five days of symptom onset. How can molnupiravir help with long-COVID. Currently, there is some evidence supporting the use of molnupiravir to decrease the risk of long-COVID.
Relevant Studies
Molnupiravir – www.covid19treatmentguidelines.nih.gov
PMC10029330 – www.ncbi.nlm.nih.gov
WHO 2019 NCoV Post COVID 19 Condition Clinical Case Definition 2021.1 – www.who.int
How it works:
Inhibits viral replication by promoting mutations in the RNA of viruses
Dosage Form: Tablet Capsule - 200mg
Common Usage: COVID-19 infection
Precautions:
Pregnancy
There are no available human data on the use of LAGEVRIO in pregnant individuals to evaluate the risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; therefore, LAGEVRIO is not recommended during pregnancy
Lactation
Based on the potential for adverse reactions in the infant from LAGEVRIO, breastfeeding is not recommended during treatment with LAGEVRIO and for 4 days after the final dose
Warnings
Warnings: Hypersensitivity, not recommended for those less than 18 due to bone and cartilage toxicity
Write a Review
© 2024 CompendiRx.com. All Rights Reserved. Information on Ratings and Reviews is reported by our members and is not medical advice.
Submission Date: Apr 16, 2024, 08:01AM
Last Update Date: Sep 14, 2024, 06:50PM
![](https://compendirx.com/wp-content/themes/medical-directory-child/assets/img/insta.png")
© 2024 CompendiRx.com. All Rights Reserved. Information on Ratings and Reviews is reported by our members and is not medical advice.
Related Medicines